Market Cap 272.35M
Revenue (ttm) 0.00
Net Income (ttm) -137.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 695,400
Avg Vol 1,296,480
Day's Range N/A - N/A
Shares Out 71.67M
Stochastic %K 48%
Beta 1.92
Analysts Sell
Price Target $7.30

Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 263 4333
Address:
10275 Science Center Dr., Suite 200, San Diego, United States
vu_jade
vu_jade Aug. 21 at 11:50 AM
$ZNTL havent been excited for this name in years…
0 · Reply
vu_jade
vu_jade Aug. 20 at 6:10 PM
$ZNTL long
0 · Reply
G101SPM
G101SPM Aug. 20 at 2:41 PM
#INSIDERS ​$AAT Executive Chairman / 10% owner bought 63,586 shares at $22.55 - $22.77 worth approximately $1.4 mln (transaction date 8/17). $ARE Executive Chairman bought 5,000 shares at $46.12 - $46.50 worth approximately $231K (transaction date 8/17). $LIEN Co-Chief Investment Officer, Secretary & Co-CIO, Chief Accounting Officer, and one (1) Director bought 108,284 shares combined worth approximately $1.0 mln (transaction dates 8/17-8/19). $MFP Director bought 10,900 shares at $45.05 worth approximately $491K (transaction date 8/17). $NATR 10% owner Prescott Group bought another 20,000 shares at $14.69 worth approximately $294K (transaction date 8/17). $QVCG 10% owner GoldenTree Asset Management bought another 44,942 shares at $15.241 worth approximately $682K (transaction date 8/17). $REFI co-CEO and Executive Chairman bought 70K shares combined worth approximately $725K (transaction dates were both 8/17). $ZNTL 10% owner The Walters Group bought another 4,335,000 shares worth approximately $15.2 mln (transaction date 8/14).
0 · Reply
lucabrix
lucabrix Aug. 20 at 9:24 AM
$ZNTL Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares
0 · Reply
lucabrix
lucabrix Aug. 20 at 9:12 AM
$ZNTL Dont tell me you didnt!!!
0 · Reply
_FurrrMom
_FurrrMom Aug. 19 at 11:29 PM
$PWCM looking good. Over a year cash runway, super-low borrow available, 1.8M float. Bitcoin rally could well send this $1.80 to $5.00. $ZNTL on watch for pullback entry. $JZXN as well, just need to confirm support.
0 · Reply
SamuraiX7
SamuraiX7 Aug. 19 at 10:28 PM
$ZNTL bullish form 4 big insider buy
0 · Reply
nastento
nastento Aug. 19 at 10:21 PM
$ZNTL wtf does billy know. Glad i had more time to continue to load up
1 · Reply
Sillyspuh2
Sillyspuh2 Aug. 19 at 10:19 PM
$ZNTL Billy W is in for another 4M+ shares. The gambler upping his ownership to 18.8% of the company. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://d18rn0p25nwr6d.cloudfront.net/CIK-0001725160/715a1eb3-53be-4833-92d5-a4eeb3688f01.pdf
0 · Reply
Harlyboy
Harlyboy Aug. 16 at 2:58 AM
$ZNTL what if Billy's about to buy more lol
1 · Reply
Latest News on ZNTL
Zentalis announecs common stock offering, no amount given

2026-08-16T14:13:19.000Z - 14 days ago

Zentalis announecs common stock offering, no amount given


Zentalis price target raised to $5 from $4 at Morgan Stanley

2026-08-07T13:57:02.000Z - 23 days ago

Zentalis price target raised to $5 from $4 at Morgan Stanley


Zentalis Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 25 days ago

Zentalis Pharmaceuticals Quarterly report: Q2 2026


Zentalis Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 25 days ago

Zentalis Pharmaceuticals Earnings release: Q2 2026


Zentalis Pharmaceuticals Slides: Corporate presentation

Aug 1, 2026, 8:00 AM EDT - 4 weeks ago

Zentalis Pharmaceuticals Slides: Corporate presentation


Zentalis initiated with a Buy at Rodman & Renshaw

2026-07-23T11:40:44.000Z - 5 weeks ago

Zentalis initiated with a Buy at Rodman & Renshaw


Zentalis initiated with an Outperform at Mizuho

2026-07-17T08:40:25.000Z - 6 weeks ago

Zentalis initiated with an Outperform at Mizuho


Zentalis assumed with an Outperform at Oppenheimer

2026-06-15T11:42:32.000Z - 2 months ago

Zentalis assumed with an Outperform at Oppenheimer


Zentalis Pharmaceuticals Proxy statement: Proxy filing

May 27, 2026, 8:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing


Zentalis Pharmaceuticals Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Quarterly report: Q1 2026


Zentalis Pharmaceuticals Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Earnings release: Q1 2026


Zentalis Pharmaceuticals Slides: Corporate presentation

May 12, 2026, 7:00 AM EDT - 3 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation


Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing


Zentalis Pharmaceuticals Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Zentalis Pharmaceuticals Proxy statement: Proxy filing


Zentalis price target raised to $10 from $6 at Guggenheim

2026-04-10T11:01:05.000Z - 5 months ago

Zentalis price target raised to $10 from $6 at Guggenheim


Zentalis Pharmaceuticals Slides: Corporate presentation

Apr 9, 2026, 7:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation


Zentalis Pharmaceuticals Annual report: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Zentalis Pharmaceuticals Annual report: Q4 2025


Zentalis Pharmaceuticals Earnings release: Q4 2025

Mar 26, 2026, 4:00 PM EDT - 5 months ago

Zentalis Pharmaceuticals Earnings release: Q4 2025


Zentalis Pharmaceuticals Slides: Corporate presentation

Jan 9, 2026, 6:00 AM EST - 8 months ago

Zentalis Pharmaceuticals Slides: Corporate presentation


Zentalis price target lowered to $4 from $8 at Morgan Stanley

2025-11-11T15:05:50.000Z - 10 months ago

Zentalis price target lowered to $4 from $8 at Morgan Stanley


Zentalis Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Zentalis Pharmaceuticals Earnings release: Q3 2025


Zentalis Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 10 months ago

Zentalis Pharmaceuticals Quarterly report: Q3 2025


Zentalis Pharmaceuticals Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 10 months ago

Zentalis Pharmaceuticals Slides: Corporate Presentation


Zentalis CLO Andrea Paul to depart, James Bucher to succeed

2025-08-26T20:10:19.000Z - 1 year ago

Zentalis CLO Andrea Paul to depart, James Bucher to succeed


Zentalis price target lowered to $5 from $6 at Wells Fargo

2025-08-07T10:27:10.000Z - 1 year ago

Zentalis price target lowered to $5 from $6 at Wells Fargo


Zentalis Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q2 2025


Zentalis Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q2 2025


Zentalis Pharmaceuticals Proxy statement: Proxy Filing

May 23, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing


Zentalis price target lowered to $9 from $10 at Oppenheimer

2025-05-15T13:07:58.000Z - 1 year ago

Zentalis price target lowered to $9 from $10 at Oppenheimer


Zentalis Pharmaceuticals Earnings release: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q1 2025


Zentalis Pharmaceuticals Quarterly report: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q1 2025


Zentalis Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing


Zentalis Pharmaceuticals Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Zentalis Pharmaceuticals Proxy statement: Proxy Filing


Zentalis Pharmaceuticals Earnings release: Q4 2024

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Earnings release: Q4 2024


Zentalis Pharmaceuticals Annual report: Q4 2024

Mar 26, 2025, 11:30 AM EDT - 1 year ago

Zentalis Pharmaceuticals Annual report: Q4 2024


Zentalis Pharmaceuticals Slides: FY 2025

Mar 10, 2025, 9:20 AM EDT - 1 year ago

Zentalis Pharmaceuticals Slides: FY 2025


Zentalis Pharmaceuticals Transcript: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Transcript: Study Update


Zentalis Pharmaceuticals Press release: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Press release: Study Update


Zentalis Pharmaceuticals Slides: Study Update

Jan 29, 2025, 8:00 AM EST - 1 year ago

Zentalis Pharmaceuticals Slides: Study Update


Zentalis Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Zentalis Pharmaceuticals Quarterly report: Q3 2024


FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 2 years ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc


vu_jade
vu_jade Aug. 21 at 11:50 AM
$ZNTL havent been excited for this name in years…
0 · Reply
vu_jade
vu_jade Aug. 20 at 6:10 PM
$ZNTL long
0 · Reply
G101SPM
G101SPM Aug. 20 at 2:41 PM
#INSIDERS ​$AAT Executive Chairman / 10% owner bought 63,586 shares at $22.55 - $22.77 worth approximately $1.4 mln (transaction date 8/17). $ARE Executive Chairman bought 5,000 shares at $46.12 - $46.50 worth approximately $231K (transaction date 8/17). $LIEN Co-Chief Investment Officer, Secretary & Co-CIO, Chief Accounting Officer, and one (1) Director bought 108,284 shares combined worth approximately $1.0 mln (transaction dates 8/17-8/19). $MFP Director bought 10,900 shares at $45.05 worth approximately $491K (transaction date 8/17). $NATR 10% owner Prescott Group bought another 20,000 shares at $14.69 worth approximately $294K (transaction date 8/17). $QVCG 10% owner GoldenTree Asset Management bought another 44,942 shares at $15.241 worth approximately $682K (transaction date 8/17). $REFI co-CEO and Executive Chairman bought 70K shares combined worth approximately $725K (transaction dates were both 8/17). $ZNTL 10% owner The Walters Group bought another 4,335,000 shares worth approximately $15.2 mln (transaction date 8/14).
0 · Reply
lucabrix
lucabrix Aug. 20 at 9:24 AM
$ZNTL Zentalis Pharmaceuticals (NASDAQ:ZNTL) Major Shareholder Group Walters Buys 4,335,000 Shares
0 · Reply
lucabrix
lucabrix Aug. 20 at 9:12 AM
$ZNTL Dont tell me you didnt!!!
0 · Reply
_FurrrMom
_FurrrMom Aug. 19 at 11:29 PM
$PWCM looking good. Over a year cash runway, super-low borrow available, 1.8M float. Bitcoin rally could well send this $1.80 to $5.00. $ZNTL on watch for pullback entry. $JZXN as well, just need to confirm support.
0 · Reply
SamuraiX7
SamuraiX7 Aug. 19 at 10:28 PM
$ZNTL bullish form 4 big insider buy
0 · Reply
nastento
nastento Aug. 19 at 10:21 PM
$ZNTL wtf does billy know. Glad i had more time to continue to load up
1 · Reply
Sillyspuh2
Sillyspuh2 Aug. 19 at 10:19 PM
$ZNTL Billy W is in for another 4M+ shares. The gambler upping his ownership to 18.8% of the company. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://d18rn0p25nwr6d.cloudfront.net/CIK-0001725160/715a1eb3-53be-4833-92d5-a4eeb3688f01.pdf
0 · Reply
Harlyboy
Harlyboy Aug. 16 at 2:58 AM
$ZNTL what if Billy's about to buy more lol
1 · Reply
lucabrix
lucabrix Aug. 15 at 7:37 PM
$ZNTL Market cap is 255 M If you put 170M in a bio of course you want a good discount. Few time and this is back to 5
0 · Reply
Lukey63
Lukey63 Aug. 14 at 6:20 PM
$ZNTL OK, I don’t like being diluted but I get it. It looked like they had 4-5 Q left of cash before the offering. This might get them into 2028 and viability or the ability to raise more at higher valuation in the future if trials are positive. Hoping this is the low but not adding yet. I have plenty of exposure.
0 · Reply
LabPsycho
LabPsycho Aug. 14 at 2:30 PM
$ZNTL Dumping after the stock is trending down and not on any significant positve news is not a good look. Now lots of bag holder resistance above this price - IMO, this is looking like dead or losing money for a while. Counterpoints?
0 · Reply
Sillyspuh2
Sillyspuh2 Aug. 14 at 1:55 PM
$ZNTL This is a tough one. At current burn rate, 80M of cash gets them maybe an 8-9 extra months. I don't think that will be enough to get them through phase 3. Guess they will have to hope for awesome data on phase 2 Denali in early 27, with a pop in the share price that helps them do at least one more cash raise.
0 · Reply
briefingcom
briefingcom Aug. 14 at 12:22 PM
$ZNTL: Zentalis Pharmaceuticals (-14.4%) priced an underwritten public offering of 23 mln common shares at $3.50/share for expected gross proceeds of about $80.5 mln.
0 · Reply
Harlyboy
Harlyboy Aug. 14 at 12:22 PM
$ZNTL they were not pressed for cash, what strange timing for an offering
0 · Reply
lucabrix
lucabrix Aug. 14 at 8:54 AM
$ZNTL Snackdaddy are you buying?
0 · Reply
zawojak
zawojak Aug. 14 at 6:45 AM
$ZNTL ill enter below $3.20
0 · Reply
focafoca99
focafoca99 Aug. 14 at 5:13 AM
$ZNTL priced its underwritten public offering at $3.50 per share, raising about $80.5 million.
0 · Reply
FreshRick
FreshRick Aug. 14 at 3:59 AM
$ZNTL Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offerin
0 · Reply
AlertsAndNews
AlertsAndNews Aug. 14 at 2:58 AM
$ZNTL Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering "today announced the pricing of an underwritten public offering of 23,000,000 shares of its common stock at a public offering price of $3.50 per share. The total gross proceeds to the Company from the offering are expected to be approximately $80.5 million"
0 · Reply
Gaben
Gaben Aug. 13 at 9:39 PM
$ZNTL death stock....
0 · Reply